Decoding human Intrahepatic Cholangiocarcinoma Metabolism: Unveiling the Impact of SLC2A3 on Aggressiveness and Prognosis
M.A. Polidoro,B. Franceschini,F. Milana,C. Soldani,R. Carriero,A. Aghemo,M. Donadon,G. Torzilli,R. Pastorelli,L. Brunelli,A. Lleo
DOI: https://doi.org/10.1016/j.dld.2024.01.010
IF: 5.165
2024-02-01
Digestive and Liver Disease
Abstract:Background and Aims Intrahepatic Cholangiocarcinoma (iCCA) is a cancer of the biliary epithelium with a poor prognosis and limited therapies. Understanding iCCA pathophysiology is crucial for developing effective treatments. In this scenario, tumor metabolism reprogramming, a cancer hallmark, is of interest due to its impact on tumor aggressiveness and therapy resistance. Herein, we investigated the role of upregulated glycolysis in iCCA and its interplay with aggressiveness and prognosis. Method Normal cholangiocytes (n=5) and iCCA cells (n=25) were isolated from patients resected at the Division of Hepatobiliary and General Surgery, Humanitas Clinical Institute. iCCA cell supernatants were analyzed by mass spectrometry-based targeted and untargeted metabolomic approaches. RNAseq and RT-PCR analyses were carried out to identify altered metabolic pathways in iCCA. An iCCA cell line (HuH28) was cultured under hypoxic conditions and migration assay was performed. RNAseq and clinical data of iCCA patients were obtained from a public dataset (OEP001105). Results The metabolomic analysis revealed that iCCA primary cells displayed elevated mitochondrial activity compared to normal cholangiocytes, with increased glutamine and glucose uptake. Moreover, RNAseq analysis unveiled changes in the glycolytic pathway, along with upregulation in hypoxia and epithelial-to-mesenchymal transition (EMT) pathways in iCCA cells (Fig. 1A). To better elucidate the role of glycolysis, we analyzed the expression by RT-PCR of two main glucose transporters, observing a down-regulation of SLC2A1 and a significant upregulation of SLC2A3 in iCCA cells, compared to cholangiocytes. Moreover, glucose uptake assays showed a positive correlation between glucose intake and SLC2A3 expression, underscoring its role in mediating glucose metabolism in iCCA cells, than SLC2A1. To gain insights into the interplay between hypoxia and glycolysis, HuH28 cells were cultured under hypoxic conditions, showing increased migratory ability and upregulation of SLC2A3 and N-CAD expression, compared to normoxia. We further explored the link between glycolysis and EMT, demonstrating a correlation between SLC2A3 expression and EMT markers, as ZEB1 and N-CAD, in iCCA cells. To elucidate the impact of SLC2A3 on iCCA prognosis, patients (n=151) from public RNAseq dataset were divided into low- and high-SLC2A3 expressions based on the median value. Notably, high-SLC2A3 patients displayed significantly poorer survival outcomes than low-expressing SLC2A3 patients (Fig. 1B). Conclusion This study revealed the significant upregulation of SLC2A3 in iCCA and its association with hypoxia and EMT, unveiling the interplay between metabolic reprogramming and tumor aggressiveness in iCCA. These findings emphasize the therapeutic potential of targeting SLC2A3, offering a promising avenue for intervention in iCCA.
gastroenterology & hepatology